Free shipping over $75 (USA/Canada).

PMLE Clinical Studies

Alpha-glucosylrutin and Vitamin E to prevent PMLE. The Science Behind.

 

You can find below a summary of two of the most promising research conclusions of the effectiveness of topical alpha-glucosylrutin and Vitamin E.

IN A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED CLINICAL STUDY BY HADSHIEW ET AL, THE EFFICACY OF A NEW TOPICAL FORMULATION WAS COMPARED WITH A BROAD-SPECTRUM SUNSCREEN. THE NEW PRODUCT CONTAINED 0.25% ALPHA-GLUCOSYLRUTIN (A NATURAL, MODIFIED FLAVONOID) AND 1% TOCOPHERYL ACETATE (VITAMIN E). THIRTY PATIENTS WITH A HISTORY OF PMLE WERE PRETREATED WITH THE FORMULATIONS 30 MINUTES PRIOR TO DAILY PHOTOPROVOCATION WITH UV-A IRRADIATION OF 60-100 J/CM2 TO THE UPPER ARMS.

THE AUTHORS FOUND A STATISTICALLY SIGNIFICANT DIFFERENCE (P <.001) BETWEEN THE ANTIOXIDANT-CONTAINING FORMULATIONS AND PLACEBO AND BETWEEN THE SUNSCREEN-ONLY FORMULATION. ONLY A SINGLE PATIENT TREATED WITH THE NEW ANTIOXIDANT UV-PROTECTIVE GEL FORMULATION DEVELOPED CLINICAL SIGNS OF PMLE IN THE AREA TREATED. IN COMPARISON, 62.1% OF THE PLACEBO-TREATED AREAS AND 41.3% OF THE SUNSCREEN-ONLY TREATED AREAS SHOWED MILD-TO-MODERATE SIGNS OF PMLE. THE AUTHORS SUGGESTED THAT COMBINING A POTENT ANTIOXIDANT WITH A BROAD-SPECTRUM SUNSCREEN IS FAR MORE EFFECTIVE IN PREVENTING PMLE THAN SUNSCREEN ALONE. READ COMPLETE STUDIES HERE.



JEANMOUGIN ET AL STUDIED THE EFFECTIVENESS 0.25% ALPHA-GLUCOSYL-RUTIN, 1% VITAMIN E, AND A BROAD-SPECTRUM HIGHLY UVA–PROTECTIVE SUNSCREEN (SPF 15; PERSISTENT PIGMENTATION DARKENING 6) UNDER REAL SOLAR EXPOSURE CONDITIONS IN THE SPRING AND SUMMER. THE CREAM WAS APPLIED EVERY 2 HOURS AFTER THE FIRST SUMMER EXPOSURE. NO TOPICAL OR SYSTEMIC TREATMENTS TO PREVENT PMLE WERE USED; DERMATOLOGISTS CHECKED PATIENTS AFTER THE SUMMER WAS OVER AND INTERVIEWED THEM. 

IN THIS STUDY, 52 OF 54 PATIENTS FINISHED STUDY, AND 67% OF PATIENTS HAD NO ERUPTIONS, 19% HAD MINOR ERUPTIONS, AND 13% HAD SEVERE ERUPTIONS OF PMLE. PRURITUS, WHICH HAD BEEN PRESENT IN ALL PATIENTS THE YEAR PRECEDING THE STUDY, WAS NOT OBSERVED IN 69% OF PATIENTS AND WAS UNBEARABLE FOR ONLY 3 PATIENTS (COMPARED WITH 27 PATIENTS BEFORE THE STUDY PREPARATION WAS USED). THE DERMATOLOGIC ASSESSMENT WAS THAT GLOBAL EFFICACY WAS APPROXIMATELY 80%, WITH INADEQUATE RESULTS IN 10% OF CASES; SPECIFICALLY, IT WAS DEEMED EXCELLENT FOR 35 PATIENTS AND GOOD FOR 7 PATIENTS